Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M33.3Revenue $M3.5Net Margin (%)-1,385.2Z-Score-8.3
Enterprise Value $M24.2EPS $-0.4Operating Margin %-1,569.7F-Score2
P/E(ttm))0Cash Flow Per Share $-0.1Pre-tax Margin (%)-1,385.1Higher ROA y-yN
Price/Book5.910-y EBITDA Growth Rate %0Quick Ratio4.3Cash flow > EarningsN
Price/Sales32.55-y EBITDA Growth Rate %0Current Ratio4.4Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-106.7Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)3ROE % (ttm)-182.7Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M51.6ROI % (ttm)-161.1Gross Margin Increase y-yN

Gurus Latest Trades with NBY

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found!

NBY is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


NBY: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Najafi RaminChairman 2014-12-12Buy50,000$0.650view
PAULSON THOMAS JCFO 2014-12-12Buy10,000$0.68-4.41view
Stroman David W.SVP, Ophthalmic Product Devt. 2014-12-12Buy10,000$0.66-1.52view
Najafi RaminChairman 2014-12-11Buy20,000$0.68.33view
PAULSON THOMAS JCFO 2014-12-09Buy10,000$0.67-2.99view
Najafi RaminChairman 2014-12-05Buy25,000$0.650view
Najafi RaminChairman 2014-12-02Buy18,000$0.71-8.45view
Wicks Tony D.S.Director 2014-12-02Sell20,000$0.7-7.14view
Wicks Tony D.S.Director 2014-12-01Sell10,000$0.69-5.8view
SIECZKAREK MARK MDirector 2014-06-04Buy4,800$0.89-26.97view

Press Releases about NBY :

    Quarterly/Annual Reports about NBY:

    News about NBY:

    Articles On GuruFocus.com
    Own it Feb 29 2012 
    NovaBay Pharmaceuticals Inc. (NBY) Chairman Ramin Najafi buys 1,000 Shares Aug 28 2009 
    NovaBay Pharmaceuticals, Inc. Reports Second Quarter 2009 Financial Results Aug 14 2009 

    More From Other Websites
    NovaBay Executive Officers Report Insider Buying of 143,000 Common Shares to the SEC Dec 23 2014
    Christmas Gift to People Worldwide Suffering From “Flesh Eating” Disease: NovaBay... Dec 23 2014
    Christmas Gift to People Worldwide Suffering From "Flesh Eating" Disease: NovaBay Pharmaceuticals... Dec 23 2014
    China Pioneer Pharma Joins Hand with NovaBay Pharmaceuticals and the NNFF To Offer Free New... Dec 19 2014
    NovaBay Executive Officers Report Insider Buying of 143,000 Common Shares to the SEC Dec 16 2014
    NovaBay Signs Distribution Agreement With the Biopharm Group Dec 08 2014
    NovaBay Signs Distribution Agreement With the Biopharm Group Dec 08 2014
    NovaBay’s i-Lid Cleanser Featured in Review of Optometry Dec 02 2014
    NovaBay's i-Lid Cleanser Featured in Review of Optometry Dec 02 2014
    NovaBay Pharmaceuticals will attend Annual LD MICRO Conference Dec 01 2014
    NovaBay Pharmaceuticals will attend Annual LD MICRO Conference Dec 01 2014
    White Paper Describes NovaBay’s Non-Antibiotic Anti-infective Portfolio Nov 24 2014
    White Paper Describes NovaBay’s Non-Antibiotic Anti-Infective Portfolio Nov 24 2014
    NovaBay’s NeutroPhase Cleared for Sale by Taiwan FDA Nov 18 2014
    NOVABAY PHARMACEUTICALS, INC. Financials Nov 18 2014
    NovaBay Signs Distribution Agreement with McKesson For i-Lid Cleanser Nov 17 2014
    NovaBay Signs Distribution Agreement with McKesson for i-Lid Cleanser Nov 17 2014
    10-Q for NovaBay Pharmaceuticals, Inc. Nov 14 2014
    NovaBay Pharmaceuticals Reports Third Quarter 2014 Financial Results and a Clinical/Business Update Nov 12 2014
    NovaBay Pharmaceuticals Reports Third Quarter 2014 Financial Results and a Clinical/Business Update Nov 12 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK